Funded projects:

Barratt-Due A, Pettersen K, Børresdatter-Dahl T, Holter JC, Grønli RH, Dyrhol-Riise AM, Lerum TV, Holten AR, Tonby K, Trøseid M, Skjønsberg OH, Granerud BK, Heggelund L, Kildal AB, Schjalm C, Aaløkken TM, Aukrust P, Ueland T, Mollnes TE, Halvorsen B, NOR‐Solidarity study groupThe Norwegian SARS‐CoV‐2 study group (2024)
Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients
J Intern Med (in press)
DOI 10.1111/joim.13783, PubMed 38539241

De Bortoli A, Nordøy I, Connelly JP, Viermyr HK, Bjerkreim RH, Broch K, Olsen PAS, Gude E, Fevang B, Jørgensen SF, Trøseid M, Steen T, Aukrust P, Andreassen AK, Skarpengland T (2024)
Diagnostics, treatment and outcomes of cardiac sarcoidosis in a Norwegian cohort
Int J Cardiol, 400, 131809
DOI 10.1016/j.ijcard.2024.131809, PubMed 38272129

Hites M, Lapique EL, Massonnaud CR, Belhadi D, Jamard S, Goehringer F, Danion F, Reignier J, de Castro N, Garot D, Lacombe K, Tolsma V, Faure E, Malvy D, Staub T, Courjon J, Cazenave-Roblot F, Dyrhol Riise AM, Leturnier P, Martin-Blondel G, Roger C, Akinosoglou K, Moing VL, Piroth L, Sellier P et al. (2024)
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial
J Infect, 88 (3), 106120
DOI 10.1016/j.jinf.2024.106120, PubMed 38367705